PitchSend

Investor Presentaiton

Commercialisation: Johns Hopkins COPD trial result • Has the capability of assessing regional ventilation defects, which is critical to optimising therapies. • Is a repeatable lung assessment tool in a cohort of COPD patients. • Illustrates distribution of airflow within the lungs, corresponding with COPD severity. Mean Specific Ventilation (a.u.) Ventilation Heterogeneity/ 200 400 009 800 Ventilation Heterogeneity By Disease Severity 1,200 1,000 Inspiration Expiration 1 2 GOLD score 4DMedical Limited (ASX:4DX) Investor Presentation | September 2022 Patient 2 Patient 1 0 RIGHT Visit 1 RIGHT LEFT UPPER RIGHT Normalized Specific Ventilation 3 4 Normalized Specific Ventilation 0 Upper MIDDLE Middle Lower LOWER LEFT UPPER RIGHT MIDDLE LOWER Normaland Specific Ventilation Visit 2 Normalized Specific Ventilation 1 2 R 4DMedical™ Upper LEFT Lower Middle LEFT UPPER R L MIDDLE 21 L LOWER

View entire presentation